ReviewTrends in endocrinology and metabolism: TEM2017
New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Review in Trends in endocrinology and metabolism: TEM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.Endocrine reviews · 2024Review
- Tumor metabolism in pheochromocytomas: clinical and therapeutic implications.Exploration of targeted anti-tumor therapy · 2024Review
- Case report: A rare DLST mutation in patient with metastatic pheochromocytoma: clinical implications and management challenges.Frontiers in oncology · 2024Article
- Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.Radiology. Imaging cancer · 2023Review
- Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'?Endocrine oncology (Bristol, England) · 2023Article
- Hypermetabolism and Substrate Utilization Rates in Pheochromocytoma and Functional Paraganglioma.Biomedicines · 2022Article
- Clinical and Pathological Tools for Predicting Recurrence and/or Metastasis in Patients with Pheochromocytoma and Paraganglioma.Biomedicines · 2022Review
- Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach.International journal of molecular sciences · 2022Review
- Precision Medicine in Phaeochromocytoma and Paraganglioma.Journal of personalized medicine · 2021Review
- Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers.Cancers · 2021Review
- HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.Cancers · 2021Article
- Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma.Frontiers in endocrinology · 2021Article
- Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine.Human molecular genetics · 2020Review
- Head and Neck Paragangliomas-A Genetic Overview.International journal of molecular sciences · 2020Review
- Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.The Journal of clinical endocrinology and metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pheochromocytomas and paragangliomas (PPGLs) belong to the family of neural crest cell-derived neoplasms. In up to 70% of cases they are associated with germline and somatic mutations in 15 well-characterized PPGL driver or fusion genes. PPGLs can be grouped into three main clusters, where cluster 1 includes PPGLs characterized by a pseudohypoxic signature. Although cluster 1 tumors share several common features, they exhibit unique behaviors. We present here unique insights into the imaging phenotypes of cluster 1 PPGLs based on glucose uptake, catecholamine metabolism, and somatostatin receptor expression. Recent data suggest that succinate is a major player in the imaging phenotype of succinate dehydrogenase-deficient PPGLs. This review emphasizes the emerging stromal cell-succinate interaction and highlights new perspectives in PPGL theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.